en · de · es · fr · pt
thymosin-alpha-1-notes.peptides6579.com › Data › Background And Mechanism Of Action — 2026 Update

Background And Mechanism Of Action — 2026 Update

By Editorial Desk · published 2025-08-23 · last reviewed 2025-10-01 · Data

If you have been reading about thymosin beta-4 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2025-10-01. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Mechanism of Action

Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.

Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.

Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.

免疫调节机制与信号

胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明,它可促进未成熟T细胞向成熟T细胞分化,并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子,从而更有效地呈递抗原。此外,自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体,而是调节宿主免疫应答的强度与方向。

在信号层面,Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示,它能激活髓样分化因子88依赖的通路,进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答,有助于细胞免疫。然而,具体受体和结合位点尚未完全确定,不同实验模型的结果存在差异。

Thymosin-alpha-1 at a glance

PropertyValueNotes
Amino acid length28 residuesSingle chain with an acetylated N-terminus
Molecular massApproximately 3,108 DaSmall shifts occur with counter-ion and water content
Isoelectric pointAround 3.5Low value follows from the many acidic residues
Parent moleculeN-terminal region of prothymosin alphaFree circulating form in humans is not firmly established
Common synonymsThymalfasin; T alpha 1Older literature also uses the full spelled-out form

Background, Structure, and Mechanism

Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.

Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.

Related pages on this site

Identity and Molecular Background

Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.

Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.

Background and Molecular Profile

The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.

The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.

Notes from published material

=== ER-Retention Signal === In eukaryotes, most of the newly synthesized secretory proteins are transported from the ER to the Golgi apparatus. If these proteins have a particular 4-amino-acid retention sequence for the ER's lumen, KDEL, on their C-terminus, they are retained in the ER's lumen or are routed back to the ER's lumen (in instances where they escape) via interaction with the KDEL receptor in the Golgi apparatus. If the signal is KKXX, the retention mechanism to the ER will be similar but the protein will be transmembranal.

This stratified squamous epithelium is maintained by cell division within the stratum basale, in which differentiating cells slowly displace outwards through the stratum spinosum to the stratum corneum, where cells are continually shed from the surface. In normal skin, the rate of production equals the rate of loss; about two weeks are needed for a cell to migrate from the basal cell layer to the top of the granular cell layer, and an additional two weeks to cross the stratum corneum. The dermis is the layer of skin between the epidermis and subcutaneous tissue, and comprises two sections, the papillary dermis and the reticular dermis. The superficial papillary dermis interdigitates with the overlying rete ridges of the epidermis, between which the two layers interact through the basement membrane zone. Structural components of the dermis are collagen, elastic fibers, and ground substance. Within these components are the pilosebaceous units, arrector pili muscles, and the eccrine and apocrine glands. The dermis contains two vascular networks that run parallel to the skin surface—one superficial and one deep plexus—which are connected by vertical communicating vessels. The function of blood vessels within the dermis is fourfold: to supply nutrition, to regulate temperature, to modulate inflammation, and to participate in wound healing. The subcutaneous tissue is a layer of fat between the dermis and underlying fascia.

Glucokinase has a lower affinity for glucose than the other hexokinases. Glucokinase changes conformation and/or function in parallel with rising glucose concentrations in the physiologically important range of 4–10 mM (72–180 mg/dL). It is half-saturated at a glucose concentration of about 8 mM (144 mg/dL). Glucokinase is not inhibited by physiological concentrations of its product, glucose-6-phosphate. This allows continued signal output (e.g., to trigger insulin release) amid significant amounts of its product. Another distinctive property of glucokinase is its moderate cooperativity with glucose, with a Hill coefficient (h) of about 1.7. These features allow it to regulate a "supply-driven" metabolic pathway. That is, the rate of reaction is driven by the supply of glucose, not by the demand for end products. Because of the cooperativity, the kinetic interaction of glucokinase with glucose does not follow classical Michaelis-Menten kinetics. Rather than a Km for glucose, it is more accurate to describe a half-saturation level S0.5, the concentration at which the enzyme is 50% saturated and active. The S0.5 and h result in an inflection of the curve enzyme activity as a function of glucose concentration at about 4 mM. In other words, at a glucose concentration of about 72 mg/dL, which is near the low end of the normal range, glucokinase activity is most sensitive to small changes in glucose concentration.

Sources: en.wikipedia.org

Further detail

Erythropoietin, or EPO, is a hormone that helps increase the production of red blood cells which increases the delivery of oxygen to muscles. It is commonly used among endurance athletes such as cyclists. It functions by protecting red blood cells against destruction whilst simultaneously stimulating bone marrow cells to produce more red blood cells. Potential side effects include: dehydration and an increase in blood viscosity which could result in a pulmonary embolism or stroke. Per the WADA, it is a banned substance. Urine samples can be tested via electrophoresis, and blood samples via indirect markers.

=== July–September 2007: Effects of the subprime crisis in U.S. === 15,000, 6 July 2007- The SENSEX on 6 July 2007 crossed another milestone and reached a magic figure of 15,000. It took 7 months and one day after first reaching the 14,000 milestone to touch this historic milestone. On 23 July 2007, the SENSEX touched a new high of 15,733 points. On 27 July 2007 the SENSEX witnessed a huge decline because of selling by Foreign Institutional Investors and global cues to come back to 15,160 points by noon. Following global cues and heavy selling in the international markets, the BSE SENSEX fell by 615 points in a single day on 1 August 2007.

== Biological role == Sulfur is an essential component of all living cells. It is the eighth most abundant element in the human body by weight, about equal in abundance to potassium, and slightly greater than sodium and chlorine. A 70 kg (150 lb) human body contains about 140 grams (4.9 oz) of sulfur. The main dietary source of sulfur for humans is sulfur-containing amino acids, which can be found in plant and animal proteins.

Sources: en.wikipedia.org

Supporting material

=== Growth Factors === Growth Factor enhanced grafts are produced using recombinant DNA technology. They consist of either Human Growth Factors or Morphogens (Bone Morphogenic Proteins in conjunction with a carrier medium, such as collagen).

=== Staff and infrastructure issues === In May 2024, The New Yorker published a feature article by staff writer Rachel Aviv that questioned aspects of Letby's conviction. Aviv highlighted chronic staffing shortages on the unit, noting that staff were "overtaxed" and that only one specialist neonatologist was available. She also referred to hygiene concerns, including an earlier inquest finding that an infant had died in 2014 after a breathing tube was inserted incorrectly, and drainage problems that caused blocked pipes and occasional sewage backflow in sinks, issues that had been raised by the defence at trial. Aviv also discussed a 2016 review by the Royal College of Paediatrics and Child Health (RCPCH) into increased mortality on the unit. After interviewing staff, the RCPCH concluded that medical and nursing staffing levels were inadequate and that the rise in mortality in 2015 was not confined to the neonatal unit. The report described Letby as "enthusiastic, capable and committed" and noted that staff were "very upset" about her removal from clinical duties. It characterised the suspicions held by some doctors as a "subjective view with no other evidence". In its public response, the hospital acknowledged problems with "staffing, competencies, leadership, team working and culture". Because of reporting restrictions linked to Letby's impending retrial, the online version of the New Yorker article was blocked for UK readers, a decision questioned in Parliament by Conservative MP David Davis.

The basic principles of the biosynthesis of lactobacillic acid were already clarified in 1961. Lactobacillic acid, as well as other naturally occurring cyclopropane fatty acids (also abbreviated as CFA or CPFA) are formed from the corresponding unsaturated fatty acids, which have one carbon atom less, and have a cis configuration on the cyclopropane ring. The precursor of lactobacillic acid (cis-11,12-methylenoctadecanoic acid) is thus cis-vaccenic acid (cis-11-octadecenoic acid). This was demonstrated by carbon isotope14C labeled precursors. With the help of the enzymes cyclopropane fatty acid synthase, a methylene group is added to the double bond of cis-vaccenic acid. The methylene group originates from S-adenosylmethionine. The unsaturated fatty acid is not free, but is bound as an ester within phospholipids. The reaction mechanism proceeds via the formation of a carbocation. The enzyme catalyzes the reaction only with unsaturated fatty acids whose double bond has a cis configuration; the corresponding trans isomers are not converted. When the bacteria are cultivated in a batch culture, the formation of CFA occurs suddenly at a certain point in time rather than steadily increasing in concentration. At the same time, a decrease in the concentration of the unsaturated fatty acid (as a precursor) is observed. The formation of cyclopropane fatty acid occurs at the end of the exponential phase of growth or in the early stationary growth phase.

Sources: en.wikipedia.org

Frequently asked questions

Is thymosin alpha-1 a hormone?

It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.

How does it relate to prothymosin alpha?

Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.

Which clinical areas have been studied?

Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.

胸腺素α1如何影响T细胞?

它促进未成熟T细胞分化并增强成熟T细胞的增殖与细胞因子分泌。这些作用有助于放大抗原特异性免疫应答。

Network